SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
See abstractor notes
Acute myeloid leukemia with multilineage dysplasia
Acute myeloid leukemia with prior myelodysplastic syndrome
Acute myeloid leukemia without prior myelodysplastic syndrome
An acute leukemia with 20% or more blasts in blood or marrow, and dysplasia in 2 or more myeloid cell lines, generally including megakaryocytes. Dysplasia must be present in at least 50% of the cells of at least 2 lines. May occur de novo OR following myelodysplastic/myeloproliferative disorder.
This is an AML with myelodysplasia-related changes. It is an acute leukemia with 20% or more PB or BM blasts with morphologic features of myelodysplasia OR a prior history of MDS OR myelodysplastic/myeloproliferative neoplasm OR MDS-related cytopenic abnormalities and without the specific genetic abnormalities of ANL with recurrent genetic abnormalities. These patients DO NOT have a history of prior cytotoxic or radiation therapy for an unrelated disease. The provisional diagnoses during work-up may include refractory anemia with excess blasts; acute erythroid leukemia, acute megakaryoblastic leukemia and AML, NOS.
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.